Bright Minds Biosciences Inc. (DRUG)

NASDAQ: DRUG · IEX Real-Time Price · USD
1.27
-0.03 (-2.31%)
At close: Sep 28, 2022 4:00 PM
1.29
+0.02 (1.57%)
After-hours: Sep 28, 2022 7:59 PM EDT
-2.31%
Market Cap 19.23M
Revenue (ttm) n/a
Net Income (ttm) -11.53M
Shares Out 15.14M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 319,662
Open 1.26
Previous Close 1.30
Day's Range 1.25 - 1.31
52-Week Range 0.75 - 8.95
Beta n/a
Analysts Buy
Price Target 8.80 (+592.9%)
Earnings Date n/a

About DRUG

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The ... [Read more...]

Industry Biotechnology
Founded 2019
Country Canada
Stock Exchange NASDAQ
Ticker Symbol DRUG
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is 8.8, which is an increase of 592.91% from the latest price.

Price Target
$8.8
(592.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

3 weeks ago - GlobeNewsWire

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures In predictive animal models, BMB-101 demonstrated significant reduction in ...

4 weeks ago - GlobeNewsWire

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

4 weeks ago - GlobeNewsWire

Why Are Psychedelics Stocks Up Today?

Psychedelics stocks, like Seelos Therapeutics (NASDAQ: SEEL ), Scisparc (NASDAQ: SPRC ) and Bright Minds Biosciences (NASDAQ: DRUG ), are taking off today. This morning, it was announced that the Michae...

Other symbols: SEELSPRC
1 month ago - InvestorPlace

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

1 month ago - GlobeNewsWire

Bright Minds Announces Overnight Marketed Offering of Units

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

1 month ago - GlobeNewsWire

Bright Minds Biosciences Comments on Recent Trading Activity

VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing...

1 month ago - GlobeNewsWire

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development ...

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing...

3 months ago - GlobeNewsWire

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET --

4 months ago - GlobeNewsWire

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists ...

-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, add...

4 months ago - GlobeNewsWire

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Ment...

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program —

9 months ago - GlobeNewsWire

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments. Bright Minds Biosciences (CSE:DRUG) received approval on Wednesday to effec...

10 months ago - Benzinga

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing...

10 months ago - GlobeNewsWire